Navigation Links
LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs
Date:4/20/2009

broad array of disease targets selected by strategic partners. The Company and its corporate partners currently have four compounds in clinical development and a full pipeline in late preclinical development. Santaris Pharma has since its inception raised nearly $100 million through private financing and up-front payments.

    For further information please contact
    Randi Krogsgaard, Director, Corporate Communications
    Direct phone +45-4517-9879
    Cell: +45-20488384
    E-mail: rmk@santaris.com
   http://www.santaris.com

'/>"/>
SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
2. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. TauTaTis Discovers Potent Inhibitor of Parkinsons Disease Gene Activity
5. Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor
6. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
7. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
8. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
9. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
10. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
11. Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...irstCall/ -- Omeros Corporation (Nasdaq: OMER ) t... third quarter ended September 30, 2009. For the t...ted a net loss of $3.9 million, or $1.34 per share....54 per share, for the same period in 2008. For th...y reported a net loss of $15.5 million, or $5.29 p...
(Date:11/19/2009)...wire-FirstCall/ -- Spherix Incorporated (Nasdaq: ... therapy, and a provider of technical and regulato...hnology and pharmaceutical companies, today announ...reholders. ,, At the meeting, shareholders of S...ollowing members to the Board of Directors: ,, ...
(Date:11/19/2009)...ons and recognized refractive and cataract surgery...ught their fellow surgeons up-to-date on the lates...act surgery, and ophthalmology in general at the r...y (AAO) annual meeting in San Francisco, Californi...David Huang, MD, Dr. Randy Epstein, Dr. William Tr...
(Date:11/18/2009)...ire/ -- Marrone Bio Innovations (MBI), a leader in...of effective and environmentally responsible pest ...med an IC20 company by the Investors, Circle, the ...nvesting group. ,, Companies named to the IC20 ...for all stakeholders, including investors, the env...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9Marrone Bio Innovations Named an IC20 Company 2
...il(TM) Vaccine Shipped in Record Time to Brazil ...ance, February 26 Sanofi Pasteur, the,vaccines di...y that six,million doses of Stamaril(TM)(1) yellow...uest to respond to the yellow fever epidemic in La...of Stamaril(TM) vaccine early,February and an addi...
... next 12 months - $30 M plus potential annual rev... hyperimmune product - Kedrion has in... - Incorporation of ProMetic,s prion reduction tec...acturing process, MONTREAL, Feb. 26 /PRNewswire-F...") (TSX:PLI) announced today that it has signed th...
...s to develop and manufacture next-generation pat... an advanced microfluidics-ba...dic Systems Inc.,(MFSI) today announced that it ha... leaders, Applied Biosystems (NYSE: ABI ), an App..., a United Technologies (NYSE: UTX ),business, fo...
Other Biology Technology:Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America 2Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America 3ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 2ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 3ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 4Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies' Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System 2Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies' Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System 3
(Date:11/19/2009)...n important crop in many countries of the world. I...d, and industrial materials. It also is considered...ion, molecular evolution, and genome architecture....cial collection used the first description of the ...ing questions in genetics and plant biology. The t...
(Date:11/19/2009)..., WALL, N.J., Nov. 19 B...YI), a leader in wireless public safety and finger...ed that the Special Shareholder Meeting held today...use a quorum was not present. ,, (Logo: http:/... ,, While an impressive 99.3% of the 35 million...
(Date:11/19/2009)...ETTE, Ind. - Purdue University scientists have hel...ponsible for cell wall development in maize, an ef...o produce the biomass best suited for biofuels pro...s Carpita, a professor of plant cell biology, publ... the journal Plant Physiology on Thursday (Nov. ...
Breaking Biology News(10 mins):PLoS Genetics 2009 maize genome collection 2PLoS Genetics 2009 maize genome collection 3PLoS Genetics 2009 maize genome collection 4BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3Maize cell wall genes identified, giving boost to biofuel research 2Soligenix to Present at 8th Annual BIO Investor Forum 14615 1Soligenix to Present at 8th Annual BIO Investor Forum 14615 2Soligenix to Present at 8th Annual BIO Investor Forum 14615 3Soligenix to Present at 8th Annual BIO Investor Forum 14615 4CryoLife Receives FDA Approval to Begin U S Clinical Trial for BioFoam 28R 29 5751 1CryoLife Receives FDA Approval to Begin U S Clinical Trial for BioFoam 28R 29 5751 2CryoLife Receives FDA Approval to Begin U S Clinical Trial for BioFoam 28R 29 5751 3CryoLife Receives FDA Approval to Begin U S Clinical Trial for BioFoam 28R 29 5751 4CryoLife Receives FDA Approval to Begin U S Clinical Trial for BioFoam 28R 29 5751 5Lumenis Receives 510K Clearance for the PolyScope Disposable Flexible Endoscope 5746 1Lumenis Receives 510K Clearance for the PolyScope Disposable Flexible Endoscope 5746 2Lumenis Receives 510K Clearance for the PolyScope Disposable Flexible Endoscope 5746 3Lumenis Receives 510K Clearance for the PolyScope Disposable Flexible Endoscope 5746 4
...RK CITY Dr. Andrew Constable of Australia, Leader... Antarctic Climate and Ecosystems Cooperative Rese...tigious 2008 Pew Fellowship in Marine Conservation...arctic krill fisheries. He will create sophisticat...dly-growing fisheries in the Southern Ocean, and w...
...code, gene that can be used to distinguish between...dentified by scientists who publish their findings...ences journal today (Monday 4 February 2008). , T...ng a small sample, could lead to new ways of easil...-rich areas like rainforests. It could also lead t...
..., N.J. -- Researchers in the Center for Maritime S...ve been awarded a grant from the United States Age...focused on enhancing mutual cooperation between sc...collaboration. , The collaboration is based on a p...ture system for a variety of marine products. The ...
Other Biology News:Dr. Andrew Constable awarded 2008 Pew Fellowship in marine conservation 2Dr. Andrew Constable awarded 2008 Pew Fellowship in marine conservation 3DNA 'barcode' identified for plants 2DNA 'barcode' identified for plants 3
Corning GAPS II Slides from Invitrogen
MUTAN SUPER EXPRESS KM 20 RXN from Takara Mirus Bio
pcDNA4/His A B & C from Invitrogen
Cassette, Hind III from Takara Mirus Bio
Biology Products: